Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selinexor and R-CHOP in untreated EBV-positive DLBCL
NCT05577364Phase 2Recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Nov 2022
- Primary completion
- Dec 2024
- Countries
- 1
01
Overview
Phase 2, open-label trial of selinexor in diffuse large B-cell lymphoma (DLBCL), sponsored by Sun Yat-sen University. Started Nov 2022; status: recruiting.
02
Drugs
selinexor
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT05577364.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05577364.